Ainos, Inc. Reports Revenue Growth and Ongoing Losses in Q3 2025

Ainos, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a modest revenue increase and ongoing operational challenges. For the three months ended September 30, 2025, the company generated revenues of $2,167, a significant increase from zero in the same period last year. For the nine months ending September 30, 2025, total revenues reached $113,037, compared to $20,729 in the prior year, primarily driven by sales of VELDONA pet supplements and VOC sensing products. Despite this revenue growth, the company reported a net loss of $2,931,702 for the third quarter, a 21% improvement from the $3,699,317 loss in the same quarter of 2024. The nine-month net loss was $10,302,714, slightly higher than the $10,209,149 loss recorded in the same period last year.

The company’s total operating expenses for the third quarter decreased by 8% to $2,785,883, down from $3,038,002 in the previous year. This reduction was attributed to lower selling, general, and administrative expenses, which fell by 22% to $795,253, as well as a slight decrease in research and development expenses. However, for the nine-month period, total operating expenses increased by 7% to $9,786,141, driven by a 35% rise in selling, general, and administrative expenses, which reached $4,159,627.

Ainos, Inc. has also undergone significant organizational changes, including a reverse stock split effective June 30, 2025, at a ratio of 1-for-5. This move was aimed at complying with Nasdaq's minimum share price requirements. The company’s total stockholders' equity decreased to $10,044,949 as of September 30, 2025, down from $15,516,310 at the end of 2024, reflecting the ongoing losses and the impact of the reverse stock split. The company’s cash and cash equivalents also declined to $1,128,217 from $3,892,919 at the end of 2024, indicating a tightening liquidity position.

In terms of operational developments, Ainos, Inc. is advancing its AI Nose technology platform, which aims to digitize scent and volatile organic compound data for various applications, including healthcare and industrial settings. The company has formed strategic partnerships to deploy this technology, including a recent three-year subscription-based order valued at $2.1 million with ASE Technology Holding Co., Ltd. for the deployment of AI Nose units across its manufacturing sites. The company is also focusing on clinical trials for its VELDONA oral interferon platform, which has received Orphan Drug Designation from the U.S. FDA for treating oral warts in HIV-positive patients.

Looking ahead, Ainos, Inc. anticipates continued investment in product development and clinical trials, with plans to leverage its existing cash reserves and potential financing options to support operations over the next twelve months. However, the company acknowledges the uncertainty surrounding its ability to secure additional funding and the potential need to reevaluate its operational plans if financial conditions do not improve.